Related Experiment Video

Updated: Jun 17, 2026

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

5.7K

Flavonoids for Myocardial Ischemia-Reperfusion Injury?

Yochai Birnbaum1, Gemma Vilahur2

  • 1The Section of Cardiology, the Department of Medicine, Baylor College of Medicine, 7200 Cambridge Street, MS BCM620, Houston, TX, 77030, USA. ybirnbau@bcm.edu.

Cardiovascular Drugs and Therapy
|March 31, 2025
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.2K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

240

Related Experiment Videos

Last Updated: Jun 17, 2026

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury
07:23

Improved Rodent Model of Myocardial Ischemia and Reperfusion Injury

Published on: March 7, 2022

5.7K
Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
05:41

Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control

Published on: December 16, 2022

3.2K
Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation
09:53

Herbal Munziq Ameliorates Myocardial Ischemia-Reperfusion Injury by Inhibiting Inflammation

Published on: January 10, 2025

240

Related Concept Videos

Ischemic Heart Disease: Overview01:17

Ischemic Heart Disease: Overview

Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and narrowing...
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...

Articles linked to this work by shared authors, journal, and citation graph.

Brain cells neuroprotection induced by TNF-α and LRP5.

Vascular pharmacology·2026

Financial Toxicity: Inequities and Impact on Cardiovascular Disease.

Arteriosclerosis, thrombosis, and vascular biology·2026

Antithrombotic therapy for secondary prevention in patients with acute coronary syndromes treated with percutaneous coronary intervention: options for personalization to reduce bleeding or ischaemic risks. A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology A Clinical Consensus Statement of the ESC Working Group on Thrombosis, the Association for Acute CardioVascular Care of the ESC, the European Association of Percutaneous Cardiovascular Interventions of the ESC, and the ESC Working Group on Cardiovascular Pharmacology.

EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology·2026

Preclinical Evaluation of Berry Extracts as a Nutritional Intervention to Alleviate Myocardial Ischemia-Reperfusion Injury and Atherosclerosis Development.

Phytotherapy research : PTR·2026

Pathophysiology, prevention, and management of coronary microvascular obstruction.

European heart journal·2026

Subcutaneous Adipose Tissue as a Metabolic Mirror: Transcriptomic Insights Into Glycaemic Dysregulation.

European journal of clinical investigation·2026

Candidate Residual Inflammatory Risk in HFpEF: A Multiorgan Framework for Longitudinal Phenotyping, Trial Enrichment, and Therapeutic Evidence Appraisal.

Cardiovascular drugs and therapy·2026

Integrating Environmental Exposure Profiles with Temporal Transcriptomics: An Explainable Machine Learning Model for Cardiovascular Disease Risk Prediction and Biological Validation.

Cardiovascular drugs and therapy·2026

Spontaneous ST-Segment Elevation in Right Precordial Leads Following Cardiac Arrest: Literature Review and Management Proposal for Ruling out Brugada Syndrome.

Cardiovascular drugs and therapy·2026

Apixaban Versus Low-Molecular-Weight Heparin in Cancer-Associated Thrombosis: An Indication-Stratified Systematic Review and Meta-Analysis of Treatment and Postoperative Prophylaxis.

Cardiovascular drugs and therapy·2026

Injectable Lipid-Lowering Therapies in Advanced Chronic Kidney Disease: Efficacy, Safety and the Dialysis Paradox.

Cardiovascular drugs and therapy·2026

Letter to "DTX1 Regulates Aortic Dissection Progression by Modulating Vascular Smooth Muscle Cell Phenotypic Switching Via Ubiquitination of ITGA5".

Cardiovascular drugs and therapy·2026

Delayed Diabetes Treatment and Persistent Hyperglycemia among Individuals with Schizophrenia: a Nationwide Register-Based Study.

Schizophrenia bulletin·2026

Evaluating Combined Sorafenib and Gemcitabine Treatment in HepG2 Cells and a NOD/SCID Mouse Xenograft Model: A Pilot Study.

Journal of visualized experiments : JoVE·2026

An Engineering-Editable Hybrid Membrane‑Camouflaged DNA Origami Drug Enables Checkpoint Blockade and Immune Activation for Triple-Negative Breast Cancer Immunotherapy.

Angewandte Chemie (International ed. in English)·2026

Chemotherapy-Activated GSK3β-DNMT1 Signaling Upregulates CD47 to Evade Macrophage Phagocytosis and Drive Temozolomide Resistance in Glioblastoma.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Restoration of m6A-Modified circPSMB1 Suppresses Chordoma Progression and Enables Local Nanotherapeutic Intervention.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026

Dietary-Derived Corchorus olitorius L. Extract Suppresses KRAS-Mutant Pancreatic Cancer by Activating Ferritinophagy-Dependent Ferroptosis.

Journal of food science·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us